| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 41, 1480-1488, Copyright © 1995 by American Association for Clinical Chemistry
K Pettersson, T Piironen, M Seppala, L Liukkonen, A Christensson, MT Matikainen, M Suonpaa, T Lovgren and H Lilja
Department of Biotechnology, University of Turku, Finland.
Generation of 15 monoclonal antibodies (MAbs) allowed construction of epitope maps and specific two-site immunofluorometric assays for free prostate-specific antigen (PSA) and PSA complexed with alpha 1- antichymotrypsin (ACT). Close correlation of PSA concentrations obtained with the use of different assays of free PSA suggested extensive similarity in immunodetection of free PSA in serum. Assays of the PSA-ACT complex overestimated the concentration of PSA-ACT in serum because of nonspecific adsorbance of ACT or cathepsin G-complexed ACT to the solid phase. This interference was substantially decreased in the presence of heparin. In studying the stability of purified PSA and PSA-ACT complexes formed in vitro, we found that the free PSA was stable during storage for 4 weeks at 35 degrees C, whereas PSA-ACT complexes largely dissociated in these conditions. The instability of PSA-ACT complexes was counteracted by storage at low temperatures, by adjusting the pH of the storage buffer between 6.8 and 7.4, and through addition of 100-1000-fold molar excess of native ACT. The ease of calibration and the accuracy of free PSA assays in comparison with assays of the PSA-ACT complex suggest that measurements of free to total PSA most accurately reflect the inverse of the proportion of PSA complexed to ACT in serum.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  S. D Mulder, J. A Heijst, C. Mulder, F. Martens, C E. Hack, P. Scheltens, M. A Blankenstein, and R. Veerhuis CSF levels of PSA and PSA-ACT complexes in Alzheimer's disease Ann Clin Biochem, November 1, 2009; 46(6): 477 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bruun, C. Savage, A. M. Cronin, J. Hugosson, H. Lilja, and A. Christensson Increase in percent free prostate-specific antigen in men with chronic kidney disease Nephrol. Dial. Transplant., April 1, 2009; 24(4): 1238 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Safarinejad Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran Ann. Onc., July 1, 2006; 17(7): 1166 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ulmert, C. Becker, J.-A. Nilsson, T. Piironen, T. Bjork, J. Hugosson, G. Berglund, and H. Lilja Reproducibility and Accuracy of Measurements of Free and Total Prostate-Specific Antigen in Serum vs Plasma after Long-Term Storage at -20 {degrees}C Clin. Chem., February 1, 2006; 52(2): 235 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Bast Jr., H. Lilja, N. Urban, D. L. Rimm, H. Fritsche, J. Gray, R. Veltri, G. Klee, A. Allen, N. Kim, et al. Translational Crossroads for Biomarkers Clin. Cancer Res., September 1, 2005; 11(17): 6103 - 6108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rej Clinical Chemistry through Clinical Chemistry: A Journal Timeline Clin. Chem., December 1, 2004; 50(12): 2415 - 2458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Piironen, B. Laursen, J. Pass, K. List, H. Gardsvoll, M. Ploug, K. Dano, and G. Hoyer-Hansen Specific Immunoassays for Detection of Intact and Cleaved Forms of the Urokinase Receptor Clin. Chem., November 1, 2004; 50(11): 2059 - 2068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Vaisanen, S. Eriksson, K. K. Ivaska, H. Lilja, M. Nurmi, and K. Pettersson Development of Sensitive Immunoassays for Free and Total Human Glandular Kallikrein 2 Clin. Chem., September 1, 2004; 50(9): 1607 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kilkkinen, J. Virtamo, M. J. Virtanen, H. Adlercreutz, D. Albanes, and P. Pietinen Serum Enterolactone Concentration Is Not Associated with Prostate Cancer Risk in a Nested Case-Control Study Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1209 - 1212. [Abstract] [Full Text]
|
|
|
|
|
|
L. Zhu, J. Leinonen, W.-M. Zhang, P. Finne, and U.-H. Stenman Dual-Label Immunoassay for Simultaneous Measurement of Prostate-specific Antigen (PSA)-{alpha}1-Antichymotrypsin Complex Together with Free or Total PSA Clin. Chem., January 1, 2003; 49(1): 97 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Leinonen, P. Wu, and U.-H. Stenman Epitope Mapping of Antibodies against Prostate-specific Antigen with Use of Peptide Libraries Clin. Chem., December 1, 2002; 48(12): 2208 - 2216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Martinez, F. Espana, M. Royo, J. M. Alapont, S. Navarro, A. Estelles, J. Aznar, C. D. Vera, and J. F. Jimenez-Cruz The Proportion of Prostate-specific Antigen (PSA) Complexed to {alpha}1-Antichymotrypsin Improves the Discrimination between Prostate Cancer and Benign Prostatic Hyperplasia in Men with a Total PSA of 10 to 30 {micro}g/L Clin. Chem., August 1, 2002; 48(8): 1251 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Niemela, J. Lovgren, M. Karp, H. Lilja, and K. Pettersson Sensitive and Specific Enzymatic Assay for the Determination of Precursor Forms of Prostate-specific Antigen after an Activation Step Clin. Chem., August 1, 2002; 48(8): 1257 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Holten-Andersen, I. J. Christensen, H. J. Nielsen, H. Lilja, G. Murphy, V. Jensen, N. Brunner, and T. Piironen Measurement of the Noncomplexed Free Fraction of Tissue Inhibitor of Metalloproteinases 1 in Plasma by Immunoassay Clin. Chem., August 1, 2002; 48(8): 1305 - 1313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Nurmikko, K. Pettersson, T. Piironen, J. Hugosson, and H. Lilja Discrimination of Prostate Cancer from Benign Disease by Plasma Measurement of Intact, Free Prostate-specific Antigen Lacking an Internal Cleavage Site at Lys145-Lys146 Clin. Chem., August 1, 2001; 47(8): 1415 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Soukka, J. Paukkunen, H. Harma, S. Lonnberg, H. Lindroos, and T. Lovgren Supersensitive Time-resolved Immunofluorometric Assay of Free Prostate-specific Antigen with Nanoparticle Label Technology Clin. Chem., July 1, 2001; 47(7): 1269 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Piironen, M. Nurmi, K. Irjala, O. Heinonen, H. Lilja, T. Lovgren, and K. Pettersson Measurement of Circulating Forms of Prostate-specific Antigen in Whole Blood Immediately after Venipuncture: Implications for Point-of-Care Testing Clin. Chem., April 1, 2001; 47(4): 703 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Peter, C. Unverzagt, T. N. Krogh, O. Vorm, and W. Hoesel Identification of Precursor Forms of Free Prostate-specific Antigen in Serum of Prostate Cancer Patients by Immunosorption and Mass Spectrometry Cancer Res., February 1, 2001; 61(3): 957 - 962. [Abstract] [Full Text]
|
|
|
|
|
|
C. Stephan, K. Jung, M. Lein, P. Sinha, D. Schnorr, and S. A. Loening Molecular Forms of Prostate-specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1133 - 1147. [Abstract] [Full Text]
|
|
|
|
|
|
P. Nurmikko, V. Vaisanen, T. Piironen, S. Lindgren, H. Lilja, and K. Pettersson Production and Characterization of Novel Anti-Prostate-specific Antigen (PSA) Monoclonal Antibodies That Do Not Detect Internally Cleaved Lys145-Lys146 Inactive PSA Clin. Chem., October 1, 2000; 46(10): 1610 - 1618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Peter, C. Unverzagt, and W. Hoesel Analysis of Free Prostate-specific Antigen (PSA) after Chemical Release from the Complex with {alpha}1-Antichymotrypsin (PSA-ACT) Clin. Chem., April 1, 2000; 46(4): 474 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Becker, T. Piironen, J. Kiviniemi, H. Lilja, and K. Pettersson Sensitive and Specific Immunodetection of Human Glandular Kallikrein 2 in Serum Clin. Chem., February 1, 2000; 46(2): 198 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Jung, U. Elgeti, M. Lein, B. Brux, P. Sinha, B. Rudolph, S. Hauptmann, D. Schnorr, and S. A. Loening Ratio of Free or Complexed Prostate-specific Antigen (PSA) to Total PSA: Which Ratio Improves Differentiation between Benign Prostatic Hyperplasia and Prostate Cancer? Clin. Chem., January 1, 2000; 46(1): 55 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Fox, A. A. Reilly, and E. Schneider Effect of the Ratio of Free to Total Prostate-specific Antigen on Interassay Variability in Proficiency Test Samples Clin. Chem., August 1, 1999; 45(8): 1181 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-M. Zhang, P. Finne, J. Leinonen, S. Vesalainen, S. Nordling, and U.-H. Stenman Measurement of the Complex between Prostate-specific Antigen and {alpha}1-Protease Inhibitor in Serum Clin. Chem., June 1, 1999; 45(6): 814 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Michel, G. Deleage, J.-P. Charrier, J. Passagot, N. Battail-Poirot, G. Sibai, M. Jolivet, and C. Jolivet-Reynaud Anti-Free Prostate-specific Antigen Monoclonal Antibody Epitopes Defined by Mimotopes and Molecular Modeling Clin. Chem., May 1, 1999; 45(5): 638 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nagasaki, M. Watanabe, N. Komatsu, T. Kaneko, J. Y. Dube, T. Kajita, Y. Saitoh, and Y. Ohta Epitope Analysis of a Prostate-specific Antigen (PSA) C-Terminal-specific Monoclonal Antibody and New Aspects for the Discrepancy between Equimolar and Skewed PSA Assays Clin. Chem., April 1, 1999; 45(4): 486 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-M. Zhang, P. Finne, J. Leinonen, S. Vesalainen, S. Nordling, S. Rannikko, and U.-H. Stenman Characterization and immunological determination of the complex between prostate-specific antigen and {alpha}2-macroglobulin Clin. Chem., December 1, 1998; 44(12): 2471 - 2479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Allard, Z. Zhou, and K. K. Yeung Novel immunoassay for the measurement of complexed prostate-specific antigen in serum Clin. Chem., June 1, 1998; 44(6): 1216 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Mannello, M. Sebastiani, S. Amati, and G. Gazzanelli Prostate-specific antigen expression in a case of intracystic carcinoma of the breast: characterization of immunoreactive protein and literature surveys Clin. Chem., August 1, 1997; 43(8): 1448 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Corey, S. K. Wegner, M. J. Corey, and R. L. Vessella Prostate-specific antigen: characterization of epitopes by synthetic peptide mapping and inhibition studies Clin. Chem., April 1, 1997; 43(4): 575 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Qian, J. A. Sensibar, D. J. Zelner, A. J. Schaeffer, J. A. Finlay, H. G. Rittenhouse, and C. Lee Two-dimensional gel electrophoresis detects prostate-specific antigen–{alpha}1-antichymotrypsin complex in serum but not in prostatic fluid Clin. Chem., February 1, 1997; 43(2): 352 - 359. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
